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Objective: Dual antiplatelet therapy with clopidogrel plus acetylsalicylic acid (ASA) is superior to ASA alone in patients
with acute coronary syndromes and in those undergoing percutaneous coronary intervention. We sought to determine
whether clopidogrel plus ASA conferred benefit on limb outcomes over ASA alone in patients undergoing below-knee
bypass grafting.
Methods: Patients undergoing unilateral, below-knee bypass graft for atherosclerotic peripheral arterial disease (PAD)
were enrolled 2 to 4 days after surgery and were randomly assigned to clopidogrel 75 mg/day plus ASA 75 to 100
mg/day or placebo plus ASA 75 to 100 mg/day for 6 to 24 months. The primary efficacy endpoint was a composite of
index-graft occlusion or revascularization, above-ankle amputation of the affected limb, or death. The primary safety
endpoint was severe bleeding (Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded
coronary arteries [GUSTO] classification).
Results: In the overall population, the primary endpoint occurred in 149 of 425 patients in the clopidogrel group vs 151
of 426 patients in the placebo (plus ASA) group (hazard ratio [HR], 0.98; 95% confidence interval [CI], 0.78-1.23). In
a prespecified subgroup analysis, the primary endpoint was significantly reduced by clopidogrel in prosthetic graft
patients (HR, 0.65; 95% CI, 0.45-0.95; P  .025) but not in venous graft patients (HR, 1.25; 95% CI, 0.94-1.67, not
significant [NS]). A significant statistical interaction between treatment effect and graft type was observed (Pinteraction 
.008). Although total bleeds were more frequent with clopidogrel, there was no significant difference between the rates
of severe bleeding in the clopidogrel and placebo (plus ASA) groups (2.1% vs 1.2%).
Conclusion: The combination of clopidogrel plus ASA did not improve limb or systemic outcomes in the overall
population of PAD patients requiring below-knee bypass grafting. Subgroup analysis suggests that clopidogrel plus ASA
confers benefit in patients receiving prosthetic grafts without significantly increasing major bleeding risk. (J Vasc Surg
2010;52:825-33.)The benefit of antiplatelet therapy in patients with
peripheral arterial disease (PAD) for the secondary preven-
tion of cardiovascular (CV) events has been evaluated1-3
and recommendations made for its use.4-6 It should be
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doi:10.1016/j.jvs.2010.04.027routine practice to prescribe such agents in the absence of
contraindications. An added advantage is the potential to
reduce bypass graft occlusion.7 About 10% to 15% of pa-
tients with PAD will receive bypass grafting.4 The Anti-
platelet Trialists’ Collaboration7 found that antiplatelet
therapy was associated with a relative risk reduction of 43%
(SD 8%; P  .001) in peripheral graft occlusion. A similar
benefit was shown in a Cochrane meta-analysis8 which had
an overall positive effect on primary patency 12 months
postoperatively (odds ratio [OR], 0.59; 95% confidence
interval [CI], 0.45-0.79).
Nevertheless, despite the use of antiplatelet mono-
therapy, usually acetylsalicylic acid (ASA), a substantial
risk of graft occlusion persists. The global incidence is
reported to be 15% per year when a vein is used9 and
20% with synthetic material (polytetrafluoroethylene)10
rising to 45% and 75%, respectively, for below-knee
grafts.
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apy,11 and because of the poor prognosis associated with
secondary arterial reconstructions (reoperation),12 vitamin
K antagonists such as warfarin have gained popularity.13
Although the Dutch Bypass Oral Anticoagulants study14
reported a benefit of warfarin (target international normal-
ized ratio 3.0-4.5) over ASA 80 mg/day for venous grafts
in patients undergoing infrainguinal grafting, oral antico-
agulation was associated with more bleeding.15 Therefore,
the coumadins have not been widely accepted for this
indication.
Ticlopidine is a thienopyridine derivative16 evaluated in
243 patients undergoing infrainguinal bypass grafting,17
which showed a strong statistically significant benefit of
ticlopidine vs placebo on venous bypass patency at 6, 12,
and 24 months postoperatively (OR, 0.26; 95% CI, 0.11-
0.63; OR, 0.38; 95% CI, 0.19-0.75; and OR, 0.37; 95%
CI, 0.21-0.64, respectively).
Clopidogrel, a thienopyridine derivative, has been used
successfully to decrease the risk of CV events in patients
with PAD.2 Its effects on inhibiting platelet adenosine
diphosphate receptors complement the effects of ASA, and
might be expected to further decrease peripheral bypass
graft occlusion.
Clopidogrel was used in combination with ASA in the
Clopidogrel in Unstable Angina to Prevent Recurrent Isch-
emic Events (CURE) study,18 in which it successfully re-
duced major CV endpoints. In the Clopidogrel and Meto-
prolol in Myocardial Infarction Trial,19 clopidogrel plus
ASA produced a highly significant reduction in death,
reinfarction, or stroke (P  .002). Thus, in secondary
prevention of CV events, a combination of ASA and clopi-
dogrel conferred significant benefit. These trials led to the
hypothesis for this trial, that a combination of ASA and
clopidogrel might reduce the risk of occlusion of infrain-
guinal vascular grafts in patients with PAD, compared to
ASA alone.
METHODS
Trial design. Clopidogrel and Acetylsalicylic acid in
bypass Surgery for Peripheral Arterial disease (CASPAR)
was a prospective, multicenter, randomized, double-blind,
placebo-controlled study of the efficacy and safety of clopi-
dogrel plus ASA as compared to ASA alone in patients
undergoing unilateral below-knee arterial bypass grafting
as management for PAD (Fig 1).
The locked clean database provided the source for
statistical analysis. Approval for the study was obtained
from regional and local ethics committees, and the trial was
performed in accordance with Good Clinical Practice reg-
ulations.20 This study is registered with ClinicalTrials.gov
(NCT00174759).
Patients. Patients undergoing vascular grafting as a
treatment for PAD were eligible for recruitment to the trial
2 to 4 days after bypass surgery. The postoperative lag-
period of 2 days was selected by the vascular surgeons
involved to allow hemostasis of the surgical wound to be
complete. Patients had to satisfy inclusion criteria: age40and 80 years; informed consent was obtained before the
conduct of any study-related procedure; chronic back-
ground treatment with daily ASA, of any dose, started at
least 4 weeks before surgery (although a window of a few
days without ASA before surgery was acceptable, according
to local practice); a postrandomization dose of ASA be-
tween 75 and 100 mg/day; unilateral below-knee (ie, the
distal anastomosis was below the level of the knee joint)
bypass graft for atherosclerotic PAD; patent index graft
demonstrated during bypass surgery, or between surgery
and the time of randomization; and no clinical evidence of
graft occlusion at randomization.
The main exclusion criteria were: onset of PAD symp-
toms before the age of 40 years; nonatherosclerotic vascular
disease; patients receiving aortobifemoral, iliac-femoral, or
crossover (femoral-femoral) grafts, or undergoing periph-
eral transcutaneous angioplasty during the same surgery;
significant bleeding risk, such as current active bleeding at
the surgical site; withdrawal of an epidural catheter less than
12 hours before randomization; peptic ulceration within 12
months of randomization; previous or current intracranial
hemorrhage or hemorrhagic stroke; any history of severe
spontaneous bleeding; current warfarin therapy or antici-
pated need for warfarin; concomitant additional antiplate-
let agents or thrombolytic agents. Study drug was tempo-
rarily stopped if thrombolytic therapy became necessary
during the study.
High-dose unfractionated heparin (UFH) or low-
molecular-weight heparin (LMWH) was used during sur-
gery and up to 12 hours before randomization, according
to local practice, but not thereafter. From randomization
day, either dextran, low-dose UFH (10,000 IU/day), or
LMWH at a dose appropriate for prevention of deep ve-
nous thrombosis was permitted when indicated. Episodic
use of cyclooxygenase-2 inhibitors (not greater than 3
weeks’ continuous use) was allowed. The use of cyclooxy-
genase-1 nonsteroidal anti-inflammatory drugs was dis-
couraged but, if necessary, they were allowed only at a low
dose, for no longer than 7 days, and the study drug was
withheld for the duration of treatment.
Procedures. After providing written informed con-
Fig 1. Clopidogrel and Acetylsalicylic acid in bypass Surgery for
Peripheral Arterial disease (CASPAR) study design. R  random-
ization stratified by graft type (venous or prosthetic). ASA, Ace-
tylsalicylic acid.sent, patients were randomly assigned either to clopidogrel
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placebo plus low-dose ASA. The prespecified minimum
duration of treatment and follow-up was 6 months and the
maximum was 24 months. Study-drug assignment was
performed centrally by an interactive voice-response system
using a pre-established randomization scheme, stratified
according to the graft type (venous or prosthetic, with the
latter class including any composite graft in which pros-
thetic material was used). Within each stratum, patients
were randomized to clopidogrel or placebo in a 1:1 ratio.
Patients were considered to be randomized as soon as the
treatment allocation was given via the interactive voice-
response system. Study drug was initiated on the day of
randomization. All patients also received standard therapy
as appropriate (eg, statins, beta-blockers, wound care) at
the discretion of the investigator and other responsible
clinicians. The use of appropriate background CV risk-
reduction therapy according to International Guidelines
was emphasized to the investigators.
Follow-up evaluations (including physical examina-
tion, duplex scan, angiography, and ankle-brachial pressure
index [ABPI]) were performed at 1 month, then every 6
months thereafter until 24 months or until the end of the
trial. At these visits, patients’ compliance was assessed, and
all interventions, outcome events, and adverse events were
recorded. All patients were to be followed until a common
study end date based on the prespecified target of 193
primary outcome events. Between visits, ie, 3, 9, 15, and 21
months after randomization, the site investigator contacted
the patient by phone to permit earlier collection of data
regarding outcome events and possible adverse events, and
to encourage the patient’s compliance.
Endpoints. All occurrences of the primary endpoint
were adjudicated on a blinded basis by the Clinical End-
points Committee. The primary endpoint was defined as
the first occurrence, over the duration of follow-up, of the
following cluster of events: occlusion of the index bypass
graft documented by any imaging procedure (eg, duplex
ultrasonography scan including B-mode imaging and
Doppler ultrasound scan); or any surgical or endovascular
revascularization procedure on the index bypass graft or
para-anastomotic region; or amputation above the ankle of
the index limb; or death. Secondary endpoints included the
first occurrence of any individual component of the primary
endpoint, and the first occurrence of the following during
follow-up: CV death, or myocardial infarction, or stroke, or
any amputation above the ankle.
Analysis of the primary endpoint was also prespecified
in the two subgroups of graft type (venous or prosthetic) ie,
where those with each type of graft were examined sepa-
rately for primary endpoint occurrence between those re-
ceiving clopidogrel and those receiving placebo.
The primary safety endpoint was severe bleeding de-
fined according to the Global Utilization of Streptokinase
and Tissue plasminogen activator for Occluded coronary
arteries (GUSTO) classification.21 Moderate and mild
bleeding according to the GUSTO criteria were also exam-
ined.Statistical analyses. Based on the target number of
events (193) and expected relative efficacy, we planned to
enroll approximately 1460 patients. The incidence of pri-
mary graft occlusion for the placebo group was projected
from the ticlopidine arm of the Becquemin study,17 in
which approximately 29% of the ticlopidine-treated pa-
tients had experienced primary bypass graft occlusion/
failure or death at 24 months. A similar ‘failure’ rate would
be expected in the placebo group in the current study.
There were no available results on which to base the efficacy
of clopidogrel in this population. However, a 30% relative
risk reduction in the incidence of primary bypass graft
failure would be considered clinically important. Therefore,
a total of 193 primary events were needed to detect a 30%
relative reduction in the 2-year primary event rate from 28%
to 19.6% with 80% power at the two-sided, .05 significance
level, assuming a 21-month recruitment period and a 15%
dropout rate at 2 years. All efficacy analyses were performed
on an intention-to-treat basis, with the inclusion of all
patients according to their randomly assigned treatment
group, and the inclusion of outcomes occurring from ran-
domization of the first patient in September 2004 to the
study end date of August 2006. For the primary analysis, all
‘failures’ occurring after premature permanent discontinu-
ation of the study drug were included, follow-up evalua-
tions and study visits continued where possible, and safety
outcomes (including bleeding and adverse events) were
monitored throughout. The ‘all treated-patients’ popula-
tion (used for the safety analyses) was defined as all random-
ized patients who received at least one dose of the study
drug.
The primary efficacy of clopidogrel as compared to a
placebo was assessed using a two-sided log-rank test. The
treatment effect as measured by hazard ratio (HR) and 95%
CI was estimated using the Cox proportional hazards
model. In both these analyses, the type of graft (venous or
prosthetic) was used as the stratification factor.Multivariate
analyses of the potential risk factors for the primary out-
come were performed, including gender, smoking habit,
diabetes, medical history, and PAD stage. Cumulative inci-
dent event curves were also calculated. A statistical compar-
ison of the safety event rates in the two groups was also
performed with Pearson’s 2 test. A preplanned subgroup
analysis by graft type (venous or prosthetic) was included as
part of the statistical plan document. This document was
finalized, completed, and approved by the Steering Com-
mittee before initiation of data analysis.
RESULTS
Patient characteristics. A total of 851 patients were
enrolled, as the requisite target event number was reached
earlier than planned. Patients were enrolled in 87 sites, in
13 European countries and Australia, between September
2004 and August 2006. Of these, 425 were randomized to
receive clopidogrel and ASA (venous grafts, n  297;
prosthetic grafts, n 128), and 426 to receive placebo plus
ASA (venous grafts, n  301; prosthetic grafts, n  125).
Patient demographics and indication for bypass surgery are
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incidences of diabetes were present in both treatment
groups (39.0% and 34.8% for venous and prosthetic graft
patients, respectively). Treatment was permanently discon-
Table I. Demographics of the CASPAR population
Placebo Clopidogrel
(n  426) (n  425)
Mean age (y) (SD) 65.6 (8.5) 66.5 (8.7)
Male (%) 75.8 75.5
Mean BMI (kg/m2) (SD) 25.7 (4.2) 25.6 (4.3)
Current smoker (%) 36.4 38.8
Hypertension (%) 70.0 70.1
Hyperlipidemia (%) 48.8 50.4
CAD and/or CRVD (%) 31.0 38.4a
Diabetes (%) 38.0 37.4
Mean preoperative ABPI of the index
limb (SD) 0.46 (0.26) 0.44 (0.25)
PAD symptoms (%)
Claudication only 32.6 34.1
Rest pain 26.5 26.1
Ulcers/gangrene 39.9 39.3
Distal anastomosis (%)
Below-knee popliteal 74.8 75.5
Below-knee popliteal crural 22.1 20.7
Beyond popliteal pedal 3.1 3.8
Concomitant medication (%)
Statins 46.8 47.8
ACE inhibitors 39.9 46.7
Beta-blockers 33.9 36.8
Diuretics 30.8 34.2
ABPI,Ankle-brachial pressure index;ACE, angiotensin-converting enzyme;
BMI, body mass index; CAD, coronary artery disease; CASPAR, Clopi-
dogrel and Acetylsalicylic acid in bypass Surgery for Peripheral Arterial
disease; CRVD, cerebrovascular disease; PAD, peripheral arterial disease.
aP  .05 vs placebo.
Fig 2. Distribution of patients. ASA, Acetylsalicylic acid.tinued by 88 patients (21.0%) in the placebo group and 107patients (25.2%) in the clopidogrel group. However, none
of the results below changed when the analyses were carried
out on the on-treatment group alone. A total of 21 patients
(4.9%) in the clopidogrel group and 3 patients (0.7%) in the
placebo group discontinued medication because of bleed-
ing.
Forty-seven patients (5.5%) were withdrawn from the
study: 19 patients (2.2%) were lost to follow-up, 27 pa-
tients (3.2%) withdrew consent, and 1 patient had missing
data. Median duration of follow-up in the clopidogrel
group was 364 days (minimum–maximum: 1-598), and
364 days (2-598) in the placebo group. The median dura-
tion of trial drug administration was 351 days (2-598) and
334 days (1-594) in the clopidogrel and placebo groups,
respectively.
The means of assessment of the graft patency intraop-
eratively, perioperatively, or postoperatively are detailed in
Table II. The study drug was initiated in both groups after
a median time of 3 days (interquartile range, Q1-Q3: 2-4
days) after surgery. Seventy percent of the patients received
ASA between operation and randomization in the placebo
group compared with 76% in the clopidogrel group. Table
III shows the antithrombotic therapy in each group be-
tween surgery and randomization.
Efficacy endpoints. Follow-up with respect to the
Table II. Intraoperative, perioperative, and postoperative
patency of grafts
Placebo Clopidogrel
(n  426) (n  425)
Measurement of the intraoperative or
perioperative graft patency (%)a
Doppler 47.4 45.0
Duplex scanning 46.0 48.3
Angiography 27.9 28.5
Other 4.5 4.7
Mean postoperative ABPI of the
index limb (SD) 0.89 (0.21) 0.87 (0.21)
ABPI, Ankle-brachial pressure index.
aSome sites used more than one method/patient.
Table III. Antithrombotic and anticoagulant therapy
between surgery and randomization
Placebo
(n  426)
Clopidogrel
(n  425) Total
ASA (%) 69.7 76.2 73.0
Mean total ASA daily dose
(mg) (SD) 94.8 (31.2) 97.0 (29.4) 96.0 (30.3)
UFH (%) 29.3 25.4 27.4
LMWH (%) 72.3 74.4 73.3
Both UFH and LMWH (%) 11.7 8.2 10.0
Dextran (%) 2.1 4.5 3.3
Others (%) 1.6 3.1 2.4
ASA, Acetylsalicylic acid; LMWH, low-molecular-weight heparin; UFH,
unfractionated heparin.primary efficacy endpoint was complete in 97.8% of patients
CI, C
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and placebo group, respectively).
The primary efficacy results are shown in Fig 3 and
Table IV. There were 300 primary outcome events in the
overall population, with no statistically significant differ-
ence between the two treatment groups (HR, 0.98; 95%
CI, 0.78-1.23; P  .87).
However, in a prospectively defined analysis, there was
a significant statistical interaction between treatment effect
and type of graft used (P .008 using theWald test). There
Fig 3. Kaplan-Meier curves of time to primary outc
amputation above ankle, death) in the total population.
Table IV. Primary endpoint, graft occlusions, and
amputations split by graft type
Placebo
(n  426)
Clopidogrel
(n  425)
Hazard ratio
(95% CI)
Primary endpoint
All grafts 151 149 0.98 (0.78-1.23)
Venous 85 101 1.25 (0.94-1.67)
Prosthetic 66 48 0.65 (0.45-0.95)b
Graft occlusionsa
All grafts 97 93 0.94 (0.71-1.25)
Venous 38 52 1.45 (0.95-2.20)
Prosthetic 59 41 0.63 (0.42-0.93)c
Amputationsa
All grafts 45 31 0.68 (0.43-1.08)
Venous 21 19 0.93 (0.50-1.72)
Prosthetic 24 12 0.48 (0.24-0.96)d
Death
All grafts 17 24 1.44 (0.77-2.68)
Venous 13 18 1.43 (0.70-2.91)
Prosthetic 4 6 1.51 (0.42-5.33)
CI, Confidence interval.
P values calculated using log-rank test.
afirst episode.
bP  .025.
cP  .021.
dP  .034; all other P values were nonsignificant (P  .05).was no statistically significant difference in the incidence ofprimary events when a venous graft was used (HR, 1.25;
95%CI, 0.94-1.67). By contrast, in the 253 prosthetic graft
patients, the addition of clopidogrel resulted in a statisti-
cally significant 35% relative risk reduction in primary out-
come events (HR, 0.65; 95% CI, 0.45-0.95; P .025; Fig
4; Table IV). In placebo patients receiving a prosthetic
graft, the number of graft occlusions was 59 (47%) com-
pared with 41 (32%) in the clopidogrel group (HR, 0.63;
95% CI, 0.42-0.93; P  .021), whereas the number of
amputations above the ankle was 24 (19.2%) in the placebo
group compared with 12 (9.4%) in the clopidogrel group
(HR, 0.48; 95% CI, 0.24-0.96; P  .034). Revasculariza-
tion and death incidences were similar between treatment
groups (HR, 0.89; 95% CI, 0.65-1.23; and HR, 1.44; 95%
CI, 0.77-2.68, respectively).
In the multivariate analysis of the primary outcome
event, there was no effect of gender, smoking habit, diabe-
tes, history of CAD or cerebrovascular disease, or PAD
stage (II, III, or IV). However, there was an independent
predictive effect of graft type (HR venous vs prosthetic,
0.50; 95% CI, 0.39-0.65; P  .001), of age (HR, 65 vs
65 years: 0.71; 95% CI, 0.56-0.91; P  .006) and the
distal sites of anastomosis (popliteal vs crural/pedal: HR,
0.74; 95% CI, 0.56-0.97; P  .032). Although there was
no predictive effect of the preoperative ABPI, there was an
effect of postoperative ABPI (ABPI 0.5-0.9 vs 0.5: HR,
0.29; 95% CI, 0.16-0.50; and ABPI 0.9 vs 0.5: HR,
0.18; 95% CI, 0.10-0.32; P  .001). Interestingly, the
presence of a statin in the concomitant medication at 1
month (visit 2) was also an independent predictor of favor-
able outcome (HR, 0.75; 95% CI, 0.59-0.97; P  .028),
whereas the time from surgery to the first study drug intake,
ASA dose (100 vs100 mg/day), ASA intake, and other
antithrombotic treatments received from surgery to ran-
domization were not.
Secondary outcomes included time to graft occlusion/
event (graft occlusion/revascularization/replacement,
onfidence interval; NS, not significant.omegraft intervention/amputation above the ankle of the af-
t.
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the HR (95% CI) was 0.91 (0.71-1.15). However, for
patients receiving a prosthetic graft, this secondary out-
come was statistically significant (HR, 0.62; 95% CI, 0.42-
0.91; P  .013), as was amputation alone (HR, 0.48; 95%
CI, 0.24-0.96; P .034; Fig 5). There were no statistically
significant differences in the occurrence of first myocardial
infarction (HR, clopidogrel vs placebo: 0.81; 95% CI,
0.32-2.06; P  .66 [using the Wald test]), cardiovascular
death (HR, 1.49; 95% CI, 0.73-3.01; P  .27), stroke
(HR, 1.02; 95% CI, 0.41-2.57; P  .96), or amputation
above the ankle (HR, 0.69; 95% CI, 0.44-1.09; P  .11).
Overall, the HR of cardiovascular death, myocardial infarc-
Fig 4. Kaplan-Meier curves of time to primary outc
amputation above ankle, death) by type of graft (intent-
significant.
Fig 5. Kaplan-Meier curves of time to first amputation
graft groups. CI, Confidence interval; NS, not significantion, or stroke was 13.5% in the clopidogrel group andTable V. Bleeding complications in the overall CASPAR
population
Placebo
(n  422)
Clopidogrel
(n  426) P value
Total bleeding eventsa 30 (7.1%) 71 (16.7%)  .001
Mild 21 (5.0%) 46 (10.8%) .002
Moderate 4 (0.9%) 16 (3.8%) .007
Severe 5 (1.2%) 9 (2.1%) NS
Fatal 1 (0.2%) 2 (0.5%) –
CASPAR, Clopidogrel and Acetylsalicylic acid in bypass Surgery for Periph-
eral Arterial disease; NS, nonsignificant.
aGlobal Utilization of Streptokinase and Tissue plasminogen activator for
Occluded coronary arteries (GUSTO) classification definition (severe: intra-
cranial hemorrhage, hemodynamic compromise; moderate: transfusion butome event (graft occlusion/revascularization/replacement,
to-treat [ITT] population). CI, Confidence interval; NS, notabove the ankle of the affected limb: venous and prostheticno hemodynamic compromise; mild: no transfusion).
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P  .75).
Safety endpoints. Severe bleeding according to the
GUSTO21 definition occurred in a greater number of pa-
tients (9; 2.1%) in the clopidogrel group than the placebo
group (5; 1.2%), of which 2 and 1, respectively, were fatal.
This difference was not statistically significant (Table V). In
contrast, a statistically significant increase in the incidence
of both mild and moderate bleeding events was observed in
the clopidogrel group vs placebo (Table V). The incidence
of mild, moderate, and severe bleeding split by graft type
(prosthetic and venous) is described in Table VI.
In the safety multivariate analysis for severe and mod-
erate bleeding, the treatment group (clopidogrel vs pla-
cebo: HR, 2.84; 95% CI, 1.32-6.08; P  .007), previous
heart failure (yes vs no: HR, 3.64; 95% CI, 1.50-8.84;
P  .004), and the site of distal anastomosis (popliteal vs
crural/pedal: HR, 0.33; 95% CI, 0.16-0.66; P  .002)
were independent predictors of bleeding.
DISCUSSION
In this trial of patients requiring below-knee vascular
grafting for PAD, there was no significant benefit within
the whole population from dual clopidogrel and ASA ther-
apy in terms of the primary endpoint. This is in line with the
results of the Clopidogrel for High Atherothrombotic Risk
and Ischemic Stabilization, Management, and Avoidance
(CHARISMA) trial, which reported that although there
was a suggestion of benefit with clopidogrel in patients with
symptomatic atherothrombosis, there was no significant
benefit in the overall population that also included high-
risk primary prevention patients.22 In addition, a recent
study reports that continuation of dual antiplatelet therapy
beyond 12 to 24 months was not significantly more effec-
tive than transition to ASA monotherapy in reducing myo-
cardial infarction or cardiac death in patients who had
received a drug-eluting stent.23 These data, however, were
part of an interim analysis of two ongoing, underpowered
studies in patients at low risk upon admission,24 and require
confirmation in larger randomized clinical trials.
In contrast to these reports, in this trial, when the
preplanned subgroup of patients receiving prosthetic grafts
was analyzed separately, a statistically significant result was
seen showing that clopidogrel reduced the composite pri-
mary endpoint, and the secondary endpoints of graft occlu-
Table VI. Incidence of mild, moderate, and severe bleedi
Venous
Placebo Clopidogrel
Mild bleeding, n (%) 16 (5.4) 36 (12.1)
Moderate bleeding, n (%) 2 (0.7) 11 (3.7)
Severe bleeding, n (%) 3 (1.0) 8 (2.7)
NS, Nonsignificant.
aPearson 2 test, or when not appropriate, Fisher exact test.sion and amputation. Because the study drug assignmentwas performed centrally using a pre-established randomiza-
tion scheme, stratified according to graft type (venous or
prosthetic), these results should be robust and would sug-
gest that dual antiplatelet therapy would allow for a better
outcome for prosthetic grafts to be achieved in the future.
However, because these conclusions are based on second-
ary analyses, any clinical benefit of dual antiplatelet therapy
in the subgroup of patients with prosthetic grafts would
need to be confirmed.
This improvement in the composite graft/death end-
point was achieved at a slightly higher cost of increased
bleeding in the mild and moderate GUSTO21 bleeding
categories, to the same level as seen in other ASA and
clopidogrel combination studies, such as CURE18 and
Clopidogrel and Metoprolol in Myocardial Infarction Tri-
al.19 There were three fatal bleeds (one placebo and two
clopidogrel), but the rates of GUSTO severe bleeding were
not statistically significantly different between the treat-
ment groups. The combined incidence of moderate, severe,
and fatal bleeding was two-fold greater in the clopidogrel
group than the placebo group (placebo, 10, 2.4%; clopi-
dogrel, 27, 6.3%).
The rate of graft failure depends on the type of graft
material used and the site of the distal anastomosis, with the
highest failure rates for prosthetic grafts to the tibial arter-
ies.25 Eighty percent of all graft failures will occur within
the first 2 postoperative years due to development of graft
stenosis,26 which continues to develop at a rate of approx-
imately 5% to 7% per year causing late graft failure.27 In the
meta-analysis performed by the Cochrane ReviewGroup,28
the effect of postoperatively administered antiplatelet treat-
ment was evaluated in patients with PAD receiving infrain-
guinal bypasses. Antiplatelet treatment had an overall pos-
itive effect on primary patency 12 months postoperatively.
The size of the effect differed between patients receiving
either synthetic or venous grafts. Thus, when analysis was
limited to the subgroups receiving synthetic (polytetrafluo-
roethylene or Dacron) grafts, this effect was statistically
significant 12 months postoperatively (HR, 0.22; 95% CI,
0.12-0.38). In contrast, there was less of an effect in
patients receiving venous grafts (HR, 0.72; 95% CI, 0.51-
1.00). The level of benefit seen brings the failure rate of
these prosthetic grafts to that of their venous counterparts,
and equates to the protection given in the Dutch Bypass
Oral Anticoagulants trial by warfarin, without the cumber-
y type of graft
Prosthetic
P valuea Placebo Clopidogrel P valuea
.004 6 (4.8) 11 (8.6) NS
.012 2 (1.6) 5 (3.9) NS
NS 2 (1.6) 1 (0.8) NSng bsome need for international normalized ratio monitoring
JOURNAL OF VASCULAR SURGERY
October 2010832 Belch et aland the associated greater bleeding risk.14 Overall, those
findings and those presented here suggest that activation of
the coagulation cascade may play a predominant role in
patient outcomes after venous grafts, whereas the stimula-
tion of platelets may play a more predominant role with
prosthetic grafts.
In our study, the presenting severity of the disease did
not affect graft outcome. In contrast, the site of the distal
anastomosis did affect outcome, with the pedal/crural ves-
sels having a worse outcome than lower popliteal, and this
supports data from other studies.25 Similarly, postoperative
ABPI was linked to graft outcome, with a poorer outcome
in patients with lower ABPIs. Again, these data support
other published work in this area.29
Another intriguing result is seen with statin therapy, in
which a suggestion of potential benefit to statin takers at
visit two, in terms of the primary outcome, is suggested.
Such a multivariate analysis is hypothesis-generating rather
than confirmatory, but statins have many pleiotropic ef-
fects, in addition to lipid-lowering, per se, that could pos-
sibly explain this benefit.30
As with all studies, there are limitations and potential
confounding factors that should be considered. The pri-
mary outcome for this study was powered with an estimated
15% discontinuation rate as a factor, but over 20% of
patients in both treatment groups permanently discontin-
ued treatment. Although this is consistent with previous
clinical trials of clopidogrel, including the pivotal CURE
trial (in which 21.1% of the patients permanently discon-
tinued the study medication in the clopidogrel group),18
there is a possibility that the higher discontinuation rates
may impact the ability to detect treatment effects, although
this was not the case in this study. Finally, there are factors
that may influence graft patency, such as surgical tech-
niques, runoff during procedure, target, anastomosis loca-
tion, and individual patient considerations that were not
prospectively recorded in this study. This is particularly
important as the multicenter design of this study may
increase the variation in procedures, care, and follow-up
(eg, imaging). Reassuringly, however, no statistically signif-
icant regional or geographic variations were recorded.
In conclusion, the combination of clopidogrel plus
ASA did not significantly reduce the primary endpoint of
occlusion, revascularization procedure, above-ankle ampu-
tation, or death in the overall population of patients with
PAD requiring below-knee grafting. However, in a pre-
planned subgroup receiving a prosthetic graft, there was a
statistically significant improvement with clopidogrel for
the primary outcome of graft failure or death, reducing
rates of occlusion and amputation to levels that compare
favorably with those seen in patients receiving venous
grafts.
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